| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Behbahani Ali | Director | 2855 SAND HILL ROAD, MENLO PARK | /s/ Zachary Bambach, attorney-in-fact | 19 Aug 2025 | 0001613867 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | ADAP | Ordinary Shares with a nominal value of 0.001 GBP per share | Sale | $53,110 | -4,828,206 | -25% | $0.0110* | 14,671,794 | 15 Aug 2025 | See Note 3 | F1, F2, F3 |
| transaction | ADAP | Ordinary Shares with a nominal value of 0.001 GBP per share | Sale | $176,062 | -14,671,794 | -100% | $0.0120* | 0 | 18 Aug 2025 | See Note 3 | F1, F3, F4 |
| Id | Content |
|---|---|
| F1 | The Ordinary Shares whose sale is reported in this row are represented by American Depositary Shares ("ADSs") and are held of record by New Enterprise Associates 16, L.P. ("NEA 16"). NEA 16 holds these Ordinary Shares in the form of ADSs. Each ADS represents six Ordinary Shares of Adaptimmune Therapeutics plc (the "Issuer"). |
| F2 | The prices reported in Column 4 are per Ordinary Share and were derived from the price per ADS divided by six. The reported price of $0.011 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $0.0099 to $0.0118 per Ordinary Share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of ADSs sold at each separate price within the range set forth in this footnote. |
| F3 | The Reporting Person is a manager of NEA 16 GP, LLC ("NEA 16 GP"), which is the sole general partner of NEA Partners 16, L.P. ("NEA Partners 16"). NEA Partners 16 is the sole general partner of NEA 16, which is the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 16 in which the Reporting Person has no pecuniary interest. |
| F4 | The prices reported in Column 4 are per Ordinary Share and were derived from the price per ADS divided by six. The reported price of $0.012 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $0.0114 to $0.0130 per Ordinary Share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of ADSs sold at each separate price within the range set forth in this footnote. |